FOR THE YEAR ENDED 31 DECEMBER 2025
BIOPAK (UK) LIMITED
COMPANY INFORMATION
BIOPAK (UK) LIMITED
CONTENTS
BIOPAK (UK) LIMITED
STRATEGIC REPORT
FOR THE YEAR ENDED 31 DECEMBER 2025
The Directors present their Strategic Report together with the audited financial statements for the year ended 31 December 2025.
Principal activities
The Company’s activity is to offer high quality food service and catering supplies and packaging, specialising in biodegradable and compostable materials.
Principal activities
The Company’s activity is to offer high quality food service and catering supplies and packaging, specialising in biodegradable and compostable materials.
For FY25 BioPak (UK) Limited saw a decline in revenue from £12.7m to £12.1m.
The market felt the impact of the continued cost-of-living crisis, with increased energy prices, rising costs for
products and less disposable income for many of our customers, resulting in a reduction in gross margin and delivered an operating Loss in the year.
Despite lower gross margin the business was able to manage its operating costs tightly, however this was offset by Distribution costs which increased significantly as a result of instability in the supply chain.
products and less disposable income for many of our customers, resulting in a reduction in gross margin and delivered an operating Loss in the year.
Despite lower gross margin the business was able to manage its operating costs tightly, however this was offset by Distribution costs which increased significantly as a result of instability in the supply chain.
BioPak faces several challenges that will require proactive management, including supply chain disruptions due
to increased freight costs and route changes, which has increased container transit time and has also contributed to an increase in operational costs and stock holding. To address this there have been a number of leadership changes, including the appointment of the new Managing Director, Paul Smith, who recently joined the business in August 2026.
Also, due to evolving regulations related to packaging waste and producer responsibility the business has required ongoing compliance efforts and investments in regulatory expertise.
Despite growing awareness of sustainability issues, consumer behaviour and preferences varied widely, and misconceptions about certain eco-friendly materials persisted. Educating consumers about the environmental benefits of sustainable packaging and dispelling myths through transparent communication is essential for
building trust and embracing change.
During the year a number of key member of management have left the business, and new industry experienced leadership has been put in place.
to increased freight costs and route changes, which has increased container transit time and has also contributed to an increase in operational costs and stock holding. To address this there have been a number of leadership changes, including the appointment of the new Managing Director, Paul Smith, who recently joined the business in August 2026.
Also, due to evolving regulations related to packaging waste and producer responsibility the business has required ongoing compliance efforts and investments in regulatory expertise.
Despite growing awareness of sustainability issues, consumer behaviour and preferences varied widely, and misconceptions about certain eco-friendly materials persisted. Educating consumers about the environmental benefits of sustainable packaging and dispelling myths through transparent communication is essential for
building trust and embracing change.
During the year a number of key member of management have left the business, and new industry experienced leadership has been put in place.
The business is optimistic around opportunities to reduce costs and further leverage the global expertise of the BioPak brand in 2026.
Driven by escalating environmental concerns, legislations and consumer preferences, BioPak is positioned well to benefit from opportunities that may arise with well-developed plans on cost savings.
The Company continues to invest in technology, new products, and collaborative partnerships to deliver innovative and sustainable solutions that meet the evolving needs of customers which will contribute to a more circular economy. In early 2026 work has been done on price adjustments to realign margins with costs, with a view to mitigate the impact of EPR cost and also restore competitiveness on some product categories.
Overall, the Company considers its customer portfolio to be well balanced across multiple sectors and continues to receive new customer enquiries which should help to improve the balance further. Management feels the Company is well placed to mitigate any further market volatility.
Overall, the Company considers its customer portfolio to be well balanced across multiple sectors and continues to receive new customer enquiries which should help to improve the balance further. Management feels the Company is well placed to mitigate any further market volatility.
Page 1
BIOPAK (UK) LIMITED
STRATEGIC REPORT (CONTINUED)
FOR THE YEAR ENDED 31 DECEMBER 2025
The Directors consider that, as set out under 172(1) of the Companies Act 2006, they have, in good faith, acted in a way that they consider is most likely to promote the success of the Company for the benefit of its members as a whole. In doing so, the Directors have given due regard to the interests of key stakeholder groups and have assessed the likely consequences of decisions on the Company’s long-term performance and its reputation. The following elements inform all of the Board's decision-making processes:
Strategy
During Board and operations meetings, the Directors review the strategic process and key performance indicators (KPIs) alongside the Senior Management Team to ensure that the Company remains aligned with its strategic and long-term objectives. Using a collaborative approach at all levels across the business ensures that all stakeholders’ views are heard and considered, helping to achieve a balanced decision-making process to ensure the long-term financial success of the Company.
Performance
BioPak has established KPIs across all strategic areas of the business and operations. The Directors focus on reviewing and analysing the Company performance against these KPIs to ensure that the Company is delivering the best performance for stakeholders.
Governance
The Directors at BioPak are committed to ensuring good governance. This is ensured by our governing business principles, code of conduct and various other compliance policies across the business, all of which are regularly reviewed and updated to meet the changing regulatory and business needs.
Below are our key stakeholders and how we have engaged with them in the decision-making process:
Customers
BioPak’s vision is to be the UK's leading provider of biodegradable and compostable packaging and supplies which is underpinned by our mission of ensuring our customers have their products at the right place, at the right time and in the right condition. This is delivered by working closely with our customers to understand their business needs and tailor our services to ensure that we provide the best service possible as one of their trusted business partners.
We value the feedback we receive from our customers and use this as a means to continuously improve the service that we offer in order to achieve leading customer satisfaction levels as part of our focus on a customer-centric culture.
Employees
BioPak has a strong commitment to its workforce. We attract, retain and develop talented people who care about the service that they deliver which enables us to clearly differentiate from our competitors on service quality. We recognise that people support the BioPak brand and are fundamental to meeting each of our stakeholders’ needs. The Directors and Senior Management recognise the importance of our employees’ contributions to the ongoing performance of the business and there are a variety of internal channels available aimed at facilitating communication and feedback.
Suppliers and other business partners
The maintenance of our supply chain is a critical function. We work closely with our suppliers, contractors and other business partners to ensure flexibility, strength and reliability throughout our supply chain.
Community and the environment
The Company is committed to a sustainable planet, not only through the provision of its products but also by the education often provided to potential customers who may not be aware of the impact conventional supplies and packaging have on the planet. The Company aims to maintain or improve on our current level of quality that we offer customers and help make their transition to greener products as seamless as possible.
Page 2
BIOPAK (UK) LIMITED
STRATEGIC REPORT (CONTINUED)
FOR THE YEAR ENDED 31 DECEMBER 2025
This report was approved by the board and signed on its behalf.
Page 3
BIOPAK (UK) LIMITED
DIRECTORS' REPORT
FOR THE YEAR ENDED 31 DECEMBER 2025
The Directors present their report and the financial statements for the year ended 31 December 2025.
The loss for the year, after taxation, amounted to £2,373,146 (2024: loss £726,844).
No dividends were declared during the year (2024: £Nil).
The Directors who served during the year and to the date of this report were:
Future developments are disclosed in the Company's Strategic Report.
The financial statements have been prepared on a going concern which the directors consider to be appropriate for the reasons set out in note 2.5 to the financial statements.
There have been no significant post balance sheet events.
The auditors, Bishop Fleming Audit Limited, will be proposed for reappointment in accordance with section 485 of the Companies Act 2006.
Page 4
BIOPAK (UK) LIMITED
DIRECTORS' REPORT (CONTINUED)
FOR THE YEAR ENDED 31 DECEMBER 2025
This report was approved by the board and signed on its behalf.
Page 5
BIOPAK (UK) LIMITED
DIRECTORS' RESPONSIBILITIES STATEMENT
FOR THE YEAR ENDED 31 DECEMBER 2025
The Directors are responsible for preparing the Strategic report, the Directors' report and the financial statements in accordance with applicable law and regulations.
Company law requires the Directors to prepare financial statements for each financial year. Under that law the Directors have elected to prepare the financial statements in accordance with applicable law and United Kingdom Accounting Standards (United Kingdom Generally Accepted Accounting Practice), including Financial Reporting Standard 102 ‘The Financial Reporting Standard applicable in the UK and Republic of Ireland'. Under company law the Directors must not approve the financial statements unless they are satisfied that they give a true and fair view of the state of affairs of the Company and of the profit or loss of the Company for that period.
In preparing these financial statements, the Directors are required to:
∙select suitable accounting policies for the Company's financial statements and then apply them consistently;
∙make judgements and accounting estimates that are reasonable and prudent;
∙state whether applicable UK Accounting Standards have been followed, subject to any material departures disclosed and explained in the financial statements;
∙prepare the financial statements on the going concern basis unless it is inappropriate to presume that the Company will continue in business.
The Directors are responsible for keeping adequate accounting records that are sufficient to show and explain the Company's transactions and disclose with reasonable accuracy at any time the financial position of the Company and to enable them to ensure that the financial statements comply with the Companies Act 2006. They are also responsible for safeguarding the assets of the Company and hence for taking reasonable steps for the prevention and detection of fraud and other irregularities.
Page 6
BIOPAK (UK) LIMITED
INDEPENDENT AUDITORS' REPORT TO THE MEMBERS OF BIOPAK (UK) LIMITED
We have audited the financial statements of BioPak (UK) Limited (the 'Company') for the year ended 31 December 2025, which comprise the Statement of comprehensive income, the Statement of financial position, the Statement of changes in equity and the related notes, including a summary of significant accounting policies. The financial reporting framework that has been applied in their preparation is applicable law and United Kingdom Accounting Standards, including Financial Reporting Standard 102 ‘The Financial Reporting Standard applicable in the UK and Republic of Ireland' (United Kingdom Generally Accepted Accounting Practice).
In auditing the financial statements, we have concluded that the Directors' use of the going concern basis of accounting in the preparation of the financial statements is appropriate.
Based on the work we have performed, we have not identified any material uncertainties relating to events or conditions that, individually or collectively, may cast significant doubt on the Company's ability to continue as a going concern for a period of at least twelve months from when the financial statements are authorised for issue.
Our responsibilities and the responsibilities of the Directors with respect to going concern are described in the relevant sections of this report.
The other information comprises the information included in the Annual Report other than the financial statements and our Auditors' report thereon. The Directors are responsible for the other information contained within the Annual Report. Our opinion on the financial statements does not cover the other information and, except to the extent otherwise explicitly stated in our report, we do not express any form of assurance conclusion thereon. Our responsibility is to read the other information and, in doing so, consider whether the other information is materially inconsistent with the financial statements or our knowledge obtained in the course of the audit, or otherwise appears to be materially misstated. If we identify such material inconsistencies or apparent material misstatements, we are required to determine whether this gives rise to a material misstatement in the financial statements themselves. If, based on the work we have performed, we conclude that there is a material misstatement of this other information, we are required to report that fact.
We have nothing to report in this regard.
Page 7
BIOPAK (UK) LIMITED
INDEPENDENT AUDITORS' REPORT TO THE MEMBERS OF BIOPAK (UK) LIMITED (CONTINUED)
In our opinion, based on the work undertaken in the course of the audit:
∙the information given in the Strategic report and the Directors' report for the financial year for which the financial statements are prepared is consistent with the financial statements; and
∙the Strategic report and the Directors' report have been prepared in accordance with applicable legal requirements.
In the light of the knowledge and understanding of the Company and its environment obtained in the course of the audit, we have not identified material misstatements in the Strategic report or the Directors' report.
Page 8
BIOPAK (UK) LIMITED
INDEPENDENT AUDITORS' REPORT TO THE MEMBERS OF BIOPAK (UK) LIMITED (CONTINUED)
Our objectives are to obtain reasonable assurance about whether the financial statements as a whole are free from material misstatement, whether due to fraud or error, and to issue an Auditors' report that includes our opinion. Reasonable assurance is a high level of assurance, but is not a guarantee that an audit conducted in accordance with ISAs (UK) will always detect a material misstatement when it exists. Misstatements can arise from fraud or error and are considered material if, individually or in the aggregate, they could reasonably be expected to influence the economic decisions of users taken on the basis of these financial statements.
Irregularities, including fraud, are instances of non-compliance with laws and regulations. We design procedures in line with our responsibilities, outlined above, to detect material misstatements in respect of irregularities, including fraud. The extent to which our procedures are capable of detecting irregularities, including fraud is detailed below.
In identifying and assessing risks of material misstatement in respect of irregularities, including fraud and non compliance with laws and regulations, we considered the following:
the nature of the industry and sector, control environment and business performance;
the nature of the industry and sector, control environment and business performance;
∙results of our enquiries of management and the board about their own identification and assessment of the risks of irregularities;
∙any matters we identified having obtained and reviewed the company's documentation of their policies and procedures relating to:
°identifying, evaluating and complying with laws and regulations and whether they were aware of any instances of non-compliance
°detecting and responding to the risks of fraud and whether they have knowledge of any actual, suspected or alleged fraud;
°the internal controls established to mitigate risks of fraud or non-compliance with laws and regulations;
∙the matters discussed among the audit engagement team regarding how and where fraud might occur in the financial statements and any potential indicators of fraud.
As a result of these procedures, we considered the opportunities and incentives that may exist within the organisation for fraud, and identified the highest area of risk to be in relation to revenue recognition, with a particular risk in relation to cut off. In common with all audits under ISAs (UK), we are also required to perform specific procedures to respond to the risk of management override.
We also obtained an understanding of the legal and regulatory frameworks that the company operates in, focusing on provisions of those laws and regulations that had a direct effect on the determination of material amounts and disclosures in the financial statements. The key laws and regulations we considered in this context included the UK Companies Act and tax legislation.
In addition, we considered provisions of other laws and regulations that do not have a direct effect on the financial statements but compliance with which may be fundamental to the company's ability to operate or to avoid a material penalty. These included occupational health and safety regulations, employment legislation, GDPR, anti-bribery and anti-corruption regulations.
Our procedures to respond to risks identified included the following:
∙reviewing the financial statements disclosures and testing to supporting documentation to assess compliance with provisions of relevant laws and regulations described as having a direct effect on the financial statements;
∙performing detailed transactional testing in relation to the recognition of revenue with a particular focus on the revenue cut off;
∙enquiring of management and those charged with governance concerning actual and potential litigation and claims;
∙performing analytical procedures to identify any unusual or unexpected relationships that may indicate risks of material misstatement due to fraud; and
∙in addressing the risk of fraud through management override of controls:
°testing the appropriateness of journal entries and other adjustments;
°assessing whether the judgements made in making accounting estimates are indicative of a potential
Page 9
BIOPAK (UK) LIMITED
INDEPENDENT AUDITORS' REPORT TO THE MEMBERS OF BIOPAK (UK) LIMITED (CONTINUED)
bias; and
°evaluating the business rationale of any significant transactions that are unusual or outside the normal course of business.
We also communicated relevant identified laws and regulations and potential fraud risks to all engagement team members, and remained alert to any indications of fraud or non-compliance with laws and regulations throughout the audit.
Because of the inherent limitations of an audit, there is a risk that we will not detect all irregularities, including those leading to a material misstatement in the financial statements or non-compliance with regulation. This risk increases the more that compliance with a law or regulation is removed from the events and transactions reflected in the financial statements, as we will be less likely to become aware of instances of non-compliance. The risk is also greater regarding irregularities occurring due to fraud rather than error, as fraud involves intentional concealment, forgery, collusion, omission or misrepresentation.
A further description of our responsibilities for the audit of the financial statements is located on the Financial Reporting Council's website at: www.frc.org.uk/auditorsresponsibilities. This description forms part of our Auditors' report.
This report is made solely to the Company's members, as a body, in accordance with Chapter 3 of Part 16 of the Companies Act 2006. Our audit work has been undertaken so that we might state to the Company's members those matters we are required to state to them in an Auditors' report and for no other purpose. To the fullest extent permitted by law, we do not accept or assume responsibility to anyone other than the Company and the Company's members, as a body, for our audit work, for this report, or for the opinions we have formed.
for and on behalf of
Chartered Accountants
Statutory Auditors
55 Colmore Row
B3 2AA
Page 10
BIOPAK (UK) LIMITED
STATEMENT OF COMPREHENSIVE INCOME
FOR THE YEAR ENDED 31 DECEMBER 2025
Page 11
BIOPAK (UK) LIMITED
REGISTERED NUMBER:04104861
STATEMENT OF FINANCIAL POSITION
AS AT 31 DECEMBER 2025
The financial statements were approved and authorised for issue by the board and were signed on its behalf by:
The notes on pages 14 to 27 form part of these financial statements.
Page 12
BIOPAK (UK) LIMITED
STATEMENT OF CHANGES IN EQUITY
FOR THE YEAR ENDED 31 DECEMBER 2025
Page 13
BIOPAK (UK) LIMITED
NOTES TO THE FINANCIAL STATEMENTS
FOR THE YEAR ENDED 31 DECEMBER 2025
BioPak (UK) Limited is a private company limited by shares incorporated in England and Wales. The registered office is Unit 13 Nunnery Park, Hornhill Road, Worcester, Worcestershire, WR4 0SX.
The principal activity of the Company is to offer high quality catering supplies and packaging, specialising in biodegradable and compostable materials.
The principal activity of the Company is to offer high quality catering supplies and packaging, specialising in biodegradable and compostable materials.
2.ACCOUNTING POLICIES
The financial statements have been prepared under the historical cost convention unless otherwise specified within these accounting policies and in accordance with Financial Reporting Standard 102, the Financial Reporting Standard applicable in the UK and the Republic of Ireland and the Companies Act 2006.
The preparation of financial statements in compliance with FRS 102 requires the use of certain critical accounting estimates. It also requires management to exercise judgement in applying the Company's accounting policies (see note 3).
The following principal accounting policies have been applied:
The amendments introduce revised requirements in respect of lease accounting and revenue recognition.
Revenue recognition policies under the revised requirements are consistent with those previously applied and there has been no change in the recognition of revenue.
Under the revised lease accounting requirements, the company now recognises right of use assets and corresponding lease liabilities in respect of leases previously classified as operating leases.
Revenue recognition policies under the revised requirements are consistent with those previously applied and there has been no change in the recognition of revenue.
Under the revised lease accounting requirements, the company now recognises right of use assets and corresponding lease liabilities in respect of leases previously classified as operating leases.
The adoption of the revised lease accounting requirements resulted in the recognition of right of use assets and lease liabilities at the start of the financial year.
The cumulative effect of adopting these amendments was recognised as an adjustment to opening retained earnings. The adoption did not affect revenue recognition.
The cumulative effect of adopting these amendments was recognised as an adjustment to opening retained earnings. The adoption did not affect revenue recognition.
At the transition date, right-of-use assets of £1,318,546 and lease liabilities of £1,248,290 were recognised. The early adoption of changes to FRS 102 did not have any other material impact of the Company's statement of comprehensive income, or financial position.
Page 14
BIOPAK (UK) LIMITED
NOTES TO THE FINANCIAL STATEMENTS
FOR THE YEAR ENDED 31 DECEMBER 2025
2.ACCOUNTING POLICIES (CONTINUED)
The Company has taken advantage of the following disclosure exemptions in preparing these financial statements, as permitted by the FRS 102 "The Financial Reporting Standard applicable in the UK and Republic of Ireland":
∙the requirements of Section 7 Statement of Cash Flows;
∙the requirements of Section 3 Financial Statement Presentation paragraph 3.17(d);
∙the requirements of Section 11 Financial Instruments paragraphs 11.42, 11.44 to 11.45, 11.47, 11.48(a)(iii), 11.48(a)(iv), 11.48(b) and 11.48(c);
∙the requirements of Section 12 Other Financial Instruments paragraphs 12.26 to 12.27, 12.29(a), 12.29(b) and 12.29A;
∙the requirements of Section 33 Related Party Disclosures paragraph 33.7.
This information is included in the consolidated financial statements of Duni AB as at 31 December 2025 and these financial statements may be obtained from Duni AB, Box 237, SE-201 22 MALMO, Sweden.
As of December 31, 2025, the company had net current liabilities of £94,807 and the company made a loss of £2,373,146 during the year. At the year end the company owed net balance due to group companies of £3,234,231. The financial statements have been prepared on a going concern basis which the directors consider to be appropriate for the reasons set out herein.
The Company meets its day to day working capital requirements from its operational cashflows and funding provided by an intermediate parent company, BioPak Pty Ltd. The directors have prepared cashflow forecasts and have performed a going concern assessment which indicates that, under both the base case and plausible downside scenario, the company will have sufficient funds to continue to meet its financial obligations as they fall due for at least 12 months from the date of approval of these financial statements. These forecasts are dependent upon BioPak Pty Ltd continuing to provide additional financial support during this period and the group companies not seeking repayment of the amounts currently due to them.
The directors have received confirmation from BioPak Pty Ltd that any amounts due to the group companies will not be called upon during the going concern assessment period and that it will continue to provide ongoing financial support to the company for a period of at least 12 months from the date of approval of these financial statements. As with any company placing reliance other entities for support, the directors acknowledge that there can be no certainty that this support will continue although at the date of approval of these financial statements, they have no reason to believe that it will not do so.
Consequently, the directors are confident that the Company will have sufficient funds to continue to meet its financial obligations as they fall due for at least 12 months from the date of approval of these financial statements and therefore have prepared the financial statements on a going concern basis.
Page 15
BIOPAK (UK) LIMITED
NOTES TO THE FINANCIAL STATEMENTS
FOR THE YEAR ENDED 31 DECEMBER 2025
2.ACCOUNTING POLICIES (CONTINUED)
Functional and presentation currency
Transactions and balances
Company and the revenue can be reliably measured. Revenue is measured as the fair value of the
consideration received or receivable, excluding discounts, rebates, value added tax and other sales
taxes. The following criteria must also be met before revenue is recognised:
Sales of goods
Revenue from the sale of goods is recognised at the point at which control of the goods transfers to
the customer. This occurs on delivery of the goods to the customer, as this is the point at which the
customer obtains control and the company has no remaining performance obligations.
Payment terms are agreed with customers in advance and are typically settled within normal credit
terms. Amounts receivable are recognised net of any expected returns or allowances.
Grants of a revenue nature are recognised in the Statement of comprehensive income in the same period as the related expenditure.
Page 16
BIOPAK (UK) LIMITED
NOTES TO THE FINANCIAL STATEMENTS
FOR THE YEAR ENDED 31 DECEMBER 2025
2.ACCOUNTING POLICIES (CONTINUED)
Page 17
BIOPAK (UK) LIMITED
NOTES TO THE FINANCIAL STATEMENTS
FOR THE YEAR ENDED 31 DECEMBER 2025
2.ACCOUNTING POLICIES (CONTINUED)
Depreciation is charged so as to allocate the cost of assets less their residual value over their estimated useful lives, using the straight-line method.
The estimated useful lives range as follows:
The assets' residual values, useful lives and depreciation methods are reviewed, and adjusted prospectively if appropriate, or if there is an indication of a significant change since the last reporting date.
Gains and losses on disposals are determined by comparing the proceeds with the carrying amount and are recognised in profit or loss.
Page 18
BIOPAK (UK) LIMITED
NOTES TO THE FINANCIAL STATEMENTS
FOR THE YEAR ENDED 31 DECEMBER 2025
2.ACCOUNTING POLICIES (CONTINUED)
The company accounts for leases in accordance with FRS 102, Section 20: Leases.
At inception, the company assesses whether a contract contains a lease. A lease is defined as a contract that conveys the right to use an asset for a period of time in exchange for consideration.
At inception, the company assesses whether a contract contains a lease. A lease is defined as a contract that conveys the right to use an asset for a period of time in exchange for consideration.
As a lessee
At the commencement date, a right-of-use asset and a corresponding lease liability are recognised.
The lease liability is initially measured at the present value of lease payments due over the lease term, discounted at the rate implicit in the lease or, if not readily determinable, the company’s incremental or obtainable borrowing rate.
The right-of-use asset is measured at the amount of the lease liability and takes into account the value of lease incentives such as rent-free periods.
After initial recognition, the right-of-use asset is depreciated on a straight-line basis over the shorter of the asset’s useful life or the lease term.
The lease liability is subsequently measured at amortised cost using the effective interest method, with interest expense recognised in profit or loss.
The company has elected to take the exemption for recognising short-term leases as right-of-use assets and lease liabilities. It has also elected to apply the exemption for leases for which the underlying asset is of low value for all leases which meet this requirement.
Provisions are measured as the best estimate of the amount required to settle the obligation, taking into account the related risks and uncertainties.
The Company only enters into basic financial instrument transactions that result in the recognition of
financial assets and liabilities like trade and other debtors and creditors, loans from banks and other
third parties and loans to related parties.
The Company only enters into basic financial instrument transactions that result in the recognition of financial assets and liabilities like trade and other debtors and creditors, loans from banks and other third parties and loans to related parties.
Page 19
BIOPAK (UK) LIMITED
NOTES TO THE FINANCIAL STATEMENTS
FOR THE YEAR ENDED 31 DECEMBER 2025
The estimates and underlying assumptions are reviewed on an ongoing basis. Revisions to accounting estimates are recognised in the period in which the estimate is revised where the revision affects only that period, or in the period of the revision and future periods where the revision affects both current and future periods.
The whole of the Company's turnover is attributable to the procurement and sale of sustainable packaging.
Analysis of turnover by country of destination:
Page 20
BIOPAK (UK) LIMITED
NOTES TO THE FINANCIAL STATEMENTS
FOR THE YEAR ENDED 31 DECEMBER 2025
Page 21
BIOPAK (UK) LIMITED
NOTES TO THE FINANCIAL STATEMENTS
FOR THE YEAR ENDED 31 DECEMBER 2025
Page 22
BIOPAK (UK) LIMITED
NOTES TO THE FINANCIAL STATEMENTS
FOR THE YEAR ENDED 31 DECEMBER 2025
11.TAXATION (CONTINUED)
Page 23
BIOPAK (UK) LIMITED
NOTES TO THE FINANCIAL STATEMENTS
FOR THE YEAR ENDED 31 DECEMBER 2025
|
|
||||||
|
|
||||||
|
|
||||||
|
|
||||||
|
|
||||||
|
|
||||||
|
|
||||||
|
|
||||||
|
|
||||||
|
|
||||||
|
|
||||||
|
|
||||||
|
|
||||||
|
|
||||||
|
|
||||||
|
|
Page 24
BIOPAK (UK) LIMITED
NOTES TO THE FINANCIAL STATEMENTS
FOR THE YEAR ENDED 31 DECEMBER 2025
Page 25
BIOPAK (UK) LIMITED
NOTES TO THE FINANCIAL STATEMENTS
FOR THE YEAR ENDED 31 DECEMBER 2025
|
|
||
|
|
||
|
|
||
|
|
||
|
|
||
|
|
Page 26
BIOPAK (UK) LIMITED
NOTES TO THE FINANCIAL STATEMENTS
FOR THE YEAR ENDED 31 DECEMBER 2025
Share premium account
Profit and loss account
The Company has provided security as part of a group wide debt facility entered into by the parent company, BioPak Pty Ltd. Although the facility was agreed in the prior year, the security over the UK entity was not formally registered until the current period. This charge over the assets of BioPak UK Ltd serves as part of the cross-guarantees and security arrangements supporting the group’s borrowing facility.
At the balance sheet date, the Company was subject to an ongoing legal claim. The directors do not consider that a provision is required.
The Company operates a defined contribution pension scheme. The assets of the scheme are held separately from those of the Company in an independently administered fund. The pension cost charge represents contributions payable by the Company to the fund amounting to £40,660 (2024: £33,464). Contributions totaling £10,420 (2024: £5,482) were payable to the fund as at the reporting date and are included in other creditors.
The immediate parent company is Kindtoo Limited, a company incorporated in England and Wales. The ultimate parent company is Duni AB, a company incorporated in Sweden.
Page 27